| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Carcinoma, Non-Small-Cell Lung | 95 | 2024 | 5581 | 9.160 |
Why?
|
| Lung Neoplasms | 136 | 2024 | 12040 | 8.220 |
Why?
|
| Pneumonectomy | 39 | 2024 | 862 | 4.770 |
Why?
|
| Neoadjuvant Therapy | 37 | 2024 | 5238 | 2.430 |
Why?
|
| Esophagectomy | 20 | 2024 | 946 | 2.290 |
Why?
|
| Mesothelioma | 12 | 2022 | 558 | 2.170 |
Why?
|
| Esophageal Neoplasms | 24 | 2024 | 3240 | 2.020 |
Why?
|
| Pleural Neoplasms | 7 | 2022 | 485 | 1.810 |
Why?
|
| Thoracic Surgical Procedures | 8 | 2022 | 260 | 1.640 |
Why?
|
| Thoracic Wall | 3 | 2018 | 188 | 1.480 |
Why?
|
| Adenocarcinoma | 24 | 2023 | 7919 | 1.370 |
Why?
|
| Neoplasm Staging | 51 | 2024 | 14020 | 1.320 |
Why?
|
| Retrospective Studies | 82 | 2024 | 39951 | 1.080 |
Why?
|
| Humans | 188 | 2024 | 271081 | 1.060 |
Why?
|
| B7-H1 Antigen | 9 | 2023 | 1089 | 1.020 |
Why?
|
| Aged | 93 | 2024 | 73545 | 0.930 |
Why?
|
| Immunotherapy | 16 | 2024 | 3559 | 0.930 |
Why?
|
| Thoracic Neoplasms | 2 | 2018 | 363 | 0.920 |
Why?
|
| Lymph Nodes | 8 | 2021 | 3081 | 0.920 |
Why?
|
| Middle Aged | 94 | 2024 | 90521 | 0.890 |
Why?
|
| Postoperative Complications | 20 | 2024 | 5679 | 0.880 |
Why?
|
| Ipilimumab | 4 | 2023 | 765 | 0.850 |
Why?
|
| Neoplasm Recurrence, Local | 23 | 2023 | 10400 | 0.830 |
Why?
|
| Radiosurgery | 6 | 2021 | 1384 | 0.770 |
Why?
|
| Databases, Factual | 17 | 2020 | 2261 | 0.730 |
Why?
|
| Male | 99 | 2024 | 128479 | 0.730 |
Why?
|
| Small Cell Lung Carcinoma | 6 | 2023 | 417 | 0.730 |
Why?
|
| Treatment Outcome | 45 | 2024 | 33807 | 0.720 |
Why?
|
| Metastasectomy | 5 | 2023 | 209 | 0.710 |
Why?
|
| Female | 102 | 2024 | 149115 | 0.710 |
Why?
|
| Multivariate Analysis | 11 | 2023 | 4326 | 0.710 |
Why?
|
| Pleura | 1 | 2021 | 130 | 0.700 |
Why?
|
| Perioperative Care | 4 | 2020 | 447 | 0.690 |
Why?
|
| Carcinoma, Squamous Cell | 10 | 2021 | 5594 | 0.680 |
Why?
|
| Aged, 80 and over | 43 | 2022 | 31078 | 0.640 |
Why?
|
| Proportional Hazards Models | 11 | 2024 | 5102 | 0.620 |
Why?
|
| Chemotherapy, Adjuvant | 9 | 2024 | 4006 | 0.620 |
Why?
|
| Kaplan-Meier Estimate | 13 | 2024 | 6258 | 0.610 |
Why?
|
| Anastomotic Leak | 2 | 2024 | 83 | 0.610 |
Why?
|
| Lymphocytes, Tumor-Infiltrating | 8 | 2022 | 1032 | 0.610 |
Why?
|
| Thoracic Surgery, Video-Assisted | 6 | 2022 | 211 | 0.610 |
Why?
|
| Follow-Up Studies | 24 | 2023 | 15281 | 0.610 |
Why?
|
| Survival Rate | 22 | 2024 | 12535 | 0.610 |
Why?
|
| Chemoradiotherapy, Adjuvant | 5 | 2021 | 562 | 0.600 |
Why?
|
| Time Factors | 20 | 2023 | 12990 | 0.600 |
Why?
|
| Cell- and Tissue-Based Therapy | 1 | 2020 | 383 | 0.580 |
Why?
|
| Survival Analysis | 16 | 2021 | 9290 | 0.550 |
Why?
|
| Thoracoplasty | 1 | 2016 | 17 | 0.550 |
Why?
|
| Antineoplastic Agents, Immunological | 4 | 2024 | 1338 | 0.540 |
Why?
|
| Sternoclavicular Joint | 1 | 2016 | 6 | 0.530 |
Why?
|
| Lung Diseases | 3 | 2021 | 751 | 0.530 |
Why?
|
| Gene Expression Regulation, Neoplastic | 6 | 2021 | 9044 | 0.520 |
Why?
|
| Surgical Wound Infection | 2 | 2017 | 496 | 0.520 |
Why?
|
| Thoracotomy | 4 | 2022 | 218 | 0.510 |
Why?
|
| Disease-Free Survival | 15 | 2021 | 10267 | 0.510 |
Why?
|
| Esophagoscopy | 4 | 2021 | 310 | 0.510 |
Why?
|
| Tumor Microenvironment | 12 | 2024 | 3041 | 0.500 |
Why?
|
| Neutrophils | 1 | 2020 | 855 | 0.500 |
Why?
|
| Biomarkers, Tumor | 13 | 2023 | 10714 | 0.490 |
Why?
|
| Pain, Postoperative | 4 | 2021 | 663 | 0.490 |
Why?
|
| Surgical Mesh | 1 | 2016 | 212 | 0.480 |
Why?
|
| Prognosis | 27 | 2024 | 22529 | 0.480 |
Why?
|
| Molecular Targeted Therapy | 4 | 2022 | 2395 | 0.470 |
Why?
|
| Programmed Cell Death 1 Receptor | 2 | 2018 | 1095 | 0.470 |
Why?
|
| Lung | 13 | 2023 | 3288 | 0.460 |
Why?
|
| Adult | 45 | 2024 | 82171 | 0.460 |
Why?
|
| Neoplasm Invasiveness | 8 | 2019 | 4052 | 0.460 |
Why?
|
| Immunotherapy, Adoptive | 2 | 2021 | 1852 | 0.450 |
Why?
|
| Texas | 11 | 2019 | 6452 | 0.440 |
Why?
|
| Osteomyelitis | 1 | 2016 | 259 | 0.420 |
Why?
|
| Propensity Score | 5 | 2021 | 772 | 0.420 |
Why?
|
| Stomach | 3 | 2012 | 402 | 0.420 |
Why?
|
| Body Mass Index | 2 | 2017 | 2233 | 0.420 |
Why?
|
| Cancer Care Facilities | 7 | 2019 | 907 | 0.400 |
Why?
|
| Logistic Models | 10 | 2019 | 3445 | 0.400 |
Why?
|
| Omentum | 1 | 2012 | 108 | 0.390 |
Why?
|
| Combined Modality Therapy | 12 | 2023 | 9039 | 0.390 |
Why?
|
| Colorectal Neoplasms | 7 | 2023 | 3707 | 0.390 |
Why?
|
| Salvage Therapy | 7 | 2021 | 2124 | 0.380 |
Why?
|
| Cohort Studies | 12 | 2021 | 9478 | 0.380 |
Why?
|
| Analgesics, Opioid | 5 | 2021 | 1468 | 0.380 |
Why?
|
| Pain Management | 3 | 2021 | 716 | 0.380 |
Why?
|
| Breast Implants | 1 | 2016 | 375 | 0.380 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 10 | 2024 | 16720 | 0.370 |
Why?
|
| Melanoma | 3 | 2023 | 5597 | 0.370 |
Why?
|
| Sutures | 1 | 2011 | 93 | 0.370 |
Why?
|
| Pancreatic Fistula | 1 | 2011 | 102 | 0.370 |
Why?
|
| Esophageal Perforation | 1 | 2010 | 28 | 0.350 |
Why?
|
| Tomography, X-Ray Computed | 8 | 2024 | 7786 | 0.350 |
Why?
|
| 5'-Nucleotidase | 2 | 2021 | 63 | 0.350 |
Why?
|
| Young Adult | 15 | 2020 | 22293 | 0.340 |
Why?
|
| Lymphatic Metastasis | 7 | 2021 | 4969 | 0.340 |
Why?
|
| Chemoradiotherapy | 6 | 2021 | 2028 | 0.340 |
Why?
|
| Fluorodeoxyglucose F18 | 5 | 2024 | 1260 | 0.340 |
Why?
|
| Risk Assessment | 13 | 2022 | 6779 | 0.340 |
Why?
|
| Positron-Emission Tomography | 4 | 2021 | 2198 | 0.320 |
Why?
|
| Consolidation Chemotherapy | 2 | 2019 | 153 | 0.320 |
Why?
|
| Leukocytes, Mononuclear | 3 | 2022 | 709 | 0.310 |
Why?
|
| Thoracic Surgery | 2 | 2023 | 284 | 0.300 |
Why?
|
| Patient Discharge | 4 | 2021 | 699 | 0.290 |
Why?
|
| Circulating Tumor DNA | 2 | 2023 | 275 | 0.290 |
Why?
|
| Risk Factors | 16 | 2023 | 17910 | 0.290 |
Why?
|
| Sarcoma | 1 | 2018 | 1851 | 0.290 |
Why?
|
| Patient Selection | 5 | 2021 | 2032 | 0.290 |
Why?
|
| Immunologic Factors | 2 | 2021 | 670 | 0.290 |
Why?
|
| Pulmonary Disease, Chronic Obstructive | 1 | 2016 | 1064 | 0.280 |
Why?
|
| Endoscopic Mucosal Resection | 2 | 2019 | 117 | 0.280 |
Why?
|
| Pancreatectomy | 1 | 2011 | 696 | 0.280 |
Why?
|
| Length of Stay | 4 | 2024 | 2006 | 0.280 |
Why?
|
| Prospective Studies | 10 | 2024 | 13445 | 0.280 |
Why?
|
| CD8-Positive T-Lymphocytes | 7 | 2023 | 1658 | 0.270 |
Why?
|
| Precancerous Conditions | 3 | 2024 | 1061 | 0.270 |
Why?
|
| Registries | 4 | 2018 | 2221 | 0.270 |
Why?
|
| Esophagogastric Junction | 3 | 2023 | 557 | 0.270 |
Why?
|
| Surgical Flaps | 1 | 2012 | 892 | 0.260 |
Why?
|
| Opioid-Related Disorders | 3 | 2019 | 419 | 0.260 |
Why?
|
| Chest Tubes | 2 | 2024 | 119 | 0.240 |
Why?
|
| Robotic Surgical Procedures | 3 | 2021 | 535 | 0.240 |
Why?
|
| Chylothorax | 1 | 2024 | 43 | 0.230 |
Why?
|
| Transcriptome | 3 | 2021 | 1960 | 0.230 |
Why?
|
| Mutation | 11 | 2024 | 15904 | 0.230 |
Why?
|
| Thymus Neoplasms | 2 | 2020 | 416 | 0.220 |
Why?
|
| Incidence | 7 | 2021 | 5841 | 0.220 |
Why?
|
| CD3 Complex | 2 | 2022 | 320 | 0.220 |
Why?
|
| Octreotide | 1 | 2024 | 132 | 0.220 |
Why?
|
| Cytokines | 4 | 2020 | 2805 | 0.220 |
Why?
|
| Gastrointestinal Agents | 1 | 2024 | 119 | 0.220 |
Why?
|
| United States | 15 | 2023 | 15889 | 0.210 |
Why?
|
| Radiotherapy, Adjuvant | 5 | 2020 | 2272 | 0.210 |
Why?
|
| Odds Ratio | 5 | 2021 | 2311 | 0.210 |
Why?
|
| Positron Emission Tomography Computed Tomography | 3 | 2024 | 881 | 0.210 |
Why?
|
| Adolescent | 12 | 2021 | 32783 | 0.210 |
Why?
|
| Paranasal Sinuses | 1 | 2022 | 64 | 0.200 |
Why?
|
| Thyroid Diseases | 1 | 2022 | 85 | 0.200 |
Why?
|
| Chi-Square Distribution | 2 | 2017 | 1310 | 0.200 |
Why?
|
| Tumor Burden | 4 | 2023 | 2033 | 0.200 |
Why?
|
| Travel | 2 | 2023 | 203 | 0.190 |
Why?
|
| Judgment | 1 | 2021 | 41 | 0.190 |
Why?
|
| Sex Factors | 4 | 2020 | 2186 | 0.190 |
Why?
|
| Tumor Necrosis Factor Receptor Superfamily, Member 9 | 1 | 2022 | 85 | 0.190 |
Why?
|
| Pulmonary Surgical Procedures | 1 | 2021 | 25 | 0.190 |
Why?
|
| Analysis of Variance | 3 | 2018 | 2317 | 0.190 |
Why?
|
| Adenocarcinoma in Situ | 1 | 2021 | 30 | 0.190 |
Why?
|
| Patient Readmission | 3 | 2021 | 572 | 0.180 |
Why?
|
| Bupivacaine | 1 | 2020 | 74 | 0.170 |
Why?
|
| Utopias | 1 | 2019 | 1 | 0.170 |
Why?
|
| SEER Program | 3 | 2019 | 1052 | 0.170 |
Why?
|
| Fluorescent Antibody Technique | 2 | 2021 | 1123 | 0.170 |
Why?
|
| Epithelial Cells | 2 | 2024 | 1877 | 0.170 |
Why?
|
| Elective Surgical Procedures | 2 | 2012 | 249 | 0.170 |
Why?
|
| Hernia, Hiatal | 2 | 2009 | 67 | 0.170 |
Why?
|
| Postoperative Hemorrhage | 1 | 2020 | 135 | 0.170 |
Why?
|
| Carcinoma, Neuroendocrine | 2 | 2022 | 742 | 0.160 |
Why?
|
| Carcinoma, Signet Ring Cell | 1 | 2020 | 180 | 0.160 |
Why?
|
| Academic Medical Centers | 2 | 2019 | 682 | 0.160 |
Why?
|
| Microwaves | 1 | 2018 | 33 | 0.160 |
Why?
|
| Stomach Neoplasms | 2 | 2023 | 2338 | 0.160 |
Why?
|
| Genomics | 4 | 2024 | 2832 | 0.160 |
Why?
|
| Reproducibility of Results | 4 | 2023 | 6191 | 0.150 |
Why?
|
| Interleukin-2 | 1 | 2022 | 889 | 0.150 |
Why?
|
| Treatment Refusal | 1 | 2019 | 128 | 0.150 |
Why?
|
| Immunogenetics | 1 | 2018 | 18 | 0.150 |
Why?
|
| Linear Models | 2 | 2018 | 1095 | 0.150 |
Why?
|
| Carcinogenesis | 2 | 2021 | 1034 | 0.150 |
Why?
|
| Induction Chemotherapy | 2 | 2018 | 670 | 0.150 |
Why?
|
| Carcinoid Tumor | 1 | 2020 | 282 | 0.150 |
Why?
|
| Natural Language Processing | 1 | 2018 | 112 | 0.150 |
Why?
|
| Nomograms | 1 | 2020 | 312 | 0.150 |
Why?
|
| Ticlopidine | 1 | 2017 | 49 | 0.150 |
Why?
|
| Heparin | 1 | 2019 | 343 | 0.150 |
Why?
|
| T-Lymphocytes | 2 | 2020 | 3953 | 0.140 |
Why?
|
| Multimodal Imaging | 1 | 2021 | 550 | 0.140 |
Why?
|
| Disease Progression | 4 | 2021 | 6868 | 0.140 |
Why?
|
| Serine Proteases | 1 | 2017 | 19 | 0.140 |
Why?
|
| Predictive Value of Tests | 5 | 2020 | 4966 | 0.140 |
Why?
|
| Margins of Excision | 1 | 2018 | 315 | 0.140 |
Why?
|
| Dasatinib | 1 | 2020 | 881 | 0.140 |
Why?
|
| Polytetrafluoroethylene | 1 | 2017 | 109 | 0.140 |
Why?
|
| Preoperative Care | 2 | 2019 | 1580 | 0.130 |
Why?
|
| Erlotinib Hydrochloride | 1 | 2017 | 398 | 0.130 |
Why?
|
| Neoplasm Metastasis | 5 | 2021 | 5317 | 0.130 |
Why?
|
| Neuroendocrine Tumors | 1 | 2022 | 656 | 0.130 |
Why?
|
| Peritoneal Neoplasms | 1 | 2023 | 863 | 0.130 |
Why?
|
| Antigen Presentation | 1 | 2017 | 286 | 0.130 |
Why?
|
| Proto-Oncogene Proteins p21(ras) | 4 | 2024 | 1403 | 0.130 |
Why?
|
| Carcinoma, Mucoepidermoid | 1 | 2017 | 141 | 0.130 |
Why?
|
| Reference Values | 1 | 2018 | 1129 | 0.130 |
Why?
|
| Insurance Coverage | 1 | 2018 | 275 | 0.130 |
Why?
|
| Reoperation | 3 | 2019 | 1394 | 0.130 |
Why?
|
| Neoplasms, Multiple Primary | 1 | 2019 | 557 | 0.130 |
Why?
|
| Gastrointestinal Microbiome | 1 | 2024 | 972 | 0.130 |
Why?
|
| Perioperative Period | 1 | 2016 | 149 | 0.130 |
Why?
|
| Acellular Dermis | 1 | 2017 | 101 | 0.130 |
Why?
|
| Diaphragm | 1 | 2017 | 187 | 0.130 |
Why?
|
| Gene Expression Profiling | 3 | 2022 | 5143 | 0.130 |
Why?
|
| Inflammation | 2 | 2024 | 2492 | 0.130 |
Why?
|
| Anterior Temporal Lobectomy | 1 | 2015 | 34 | 0.130 |
Why?
|
| Antineoplastic Agents | 4 | 2023 | 14636 | 0.120 |
Why?
|
| Barrett Esophagus | 1 | 2021 | 560 | 0.120 |
Why?
|
| Immunomodulation | 1 | 2017 | 253 | 0.120 |
Why?
|
| Hemorrhage | 1 | 2019 | 726 | 0.120 |
Why?
|
| Smoking Cessation | 1 | 2021 | 776 | 0.120 |
Why?
|
| Receptors, Antigen, T-Cell | 2 | 2020 | 1135 | 0.120 |
Why?
|
| Platelet Aggregation Inhibitors | 1 | 2017 | 328 | 0.120 |
Why?
|
| Disease Models, Animal | 4 | 2024 | 7320 | 0.120 |
Why?
|
| Cytoreduction Surgical Procedures | 1 | 2019 | 510 | 0.120 |
Why?
|
| Macrophages | 2 | 2019 | 1333 | 0.120 |
Why?
|
| National Cancer Institute (U.S.) | 3 | 2020 | 219 | 0.120 |
Why?
|
| Image Processing, Computer-Assisted | 2 | 2021 | 1692 | 0.120 |
Why?
|
| Cisplatin | 2 | 2020 | 2499 | 0.110 |
Why?
|
| Anticoagulants | 1 | 2019 | 777 | 0.110 |
Why?
|
| Continuity of Patient Care | 1 | 2016 | 206 | 0.110 |
Why?
|
| Thymoma | 1 | 2017 | 252 | 0.110 |
Why?
|
| Taxoids | 1 | 2017 | 1019 | 0.110 |
Why?
|
| DNA Methylation | 2 | 2021 | 2770 | 0.110 |
Why?
|
| Genetic Heterogeneity | 3 | 2021 | 338 | 0.110 |
Why?
|
| Confidence Intervals | 2 | 2018 | 748 | 0.110 |
Why?
|
| Cell Differentiation | 1 | 2024 | 4105 | 0.110 |
Why?
|
| Hoarseness | 1 | 2012 | 26 | 0.110 |
Why?
|
| Immunohistochemistry | 3 | 2021 | 7645 | 0.110 |
Why?
|
| Acute Kidney Injury | 1 | 2020 | 760 | 0.100 |
Why?
|
| Health Services Accessibility | 1 | 2019 | 831 | 0.100 |
Why?
|
| Anti-Inflammatory Agents | 1 | 2016 | 453 | 0.100 |
Why?
|
| Neoplasm Proteins | 2 | 2021 | 3345 | 0.100 |
Why?
|
| Cause of Death | 1 | 2015 | 789 | 0.100 |
Why?
|
| Breast Neoplasms | 1 | 2017 | 16238 | 0.100 |
Why?
|
| Killer Cells, Natural | 1 | 2018 | 965 | 0.100 |
Why?
|
| Hospital Mortality | 1 | 2018 | 1236 | 0.100 |
Why?
|
| DNA, Neoplasm | 1 | 2017 | 1958 | 0.100 |
Why?
|
| Thyroid Neoplasms | 1 | 2022 | 1894 | 0.100 |
Why?
|
| Cough | 1 | 2012 | 125 | 0.100 |
Why?
|
| Oncogene Proteins, Fusion | 1 | 2017 | 797 | 0.100 |
Why?
|
| Emergencies | 2 | 2009 | 225 | 0.100 |
Why?
|
| Lymph Node Excision | 2 | 2018 | 2068 | 0.090 |
Why?
|
| Consensus | 3 | 2023 | 1112 | 0.090 |
Why?
|
| Radiopharmaceuticals | 3 | 2021 | 1341 | 0.090 |
Why?
|
| Anastomosis, Surgical | 1 | 2012 | 370 | 0.090 |
Why?
|
| Pancreatic Diseases | 1 | 2011 | 113 | 0.090 |
Why?
|
| Early Detection of Cancer | 1 | 2019 | 1344 | 0.090 |
Why?
|
| Patient Satisfaction | 1 | 2016 | 922 | 0.090 |
Why?
|
| Age Factors | 1 | 2020 | 5458 | 0.090 |
Why?
|
| Child | 5 | 2018 | 30596 | 0.090 |
Why?
|
| Chronic Disease | 1 | 2016 | 1822 | 0.090 |
Why?
|
| Dexamethasone | 1 | 2016 | 1516 | 0.090 |
Why?
|
| Surveys and Questionnaires | 3 | 2023 | 5938 | 0.090 |
Why?
|
| Antigens, Neoplasm | 1 | 2017 | 1581 | 0.090 |
Why?
|
| Cost of Illness | 2 | 2023 | 505 | 0.090 |
Why?
|
| Tumor Suppressor Proteins | 1 | 2018 | 1900 | 0.080 |
Why?
|
| Radiography | 1 | 2014 | 1993 | 0.080 |
Why?
|
| GPI-Linked Proteins | 2 | 2021 | 233 | 0.080 |
Why?
|
| Gastroesophageal Reflux | 1 | 2012 | 368 | 0.080 |
Why?
|
| Mucous Membrane | 1 | 2010 | 260 | 0.080 |
Why?
|
| Clone Cells | 2 | 2021 | 590 | 0.080 |
Why?
|
| RNA, Messenger | 2 | 2018 | 6343 | 0.080 |
Why?
|
| Vascular Neoplasms | 1 | 2010 | 112 | 0.080 |
Why?
|
| Glioblastoma | 1 | 2019 | 1776 | 0.080 |
Why?
|
| Telephone | 2 | 2021 | 160 | 0.080 |
Why?
|
| High-Throughput Nucleotide Sequencing | 1 | 2017 | 2359 | 0.080 |
Why?
|
| Patient Admission | 1 | 2009 | 231 | 0.080 |
Why?
|
| Antibodies, Monoclonal | 1 | 2021 | 4481 | 0.080 |
Why?
|
| Oxygen | 1 | 2012 | 789 | 0.080 |
Why?
|
| Gastrectomy | 2 | 2023 | 476 | 0.080 |
Why?
|
| Prevalence | 3 | 2010 | 3412 | 0.070 |
Why?
|
| Radiotherapy, Intensity-Modulated | 1 | 2019 | 2178 | 0.070 |
Why?
|
| Mediastinum | 2 | 2019 | 276 | 0.070 |
Why?
|
| ErbB Receptors | 3 | 2020 | 2375 | 0.070 |
Why?
|
| Cell Survival | 1 | 2013 | 3058 | 0.070 |
Why?
|
| T-Lymphocytes, Cytotoxic | 2 | 2023 | 1020 | 0.070 |
Why?
|
| Population Surveillance | 1 | 2009 | 646 | 0.070 |
Why?
|
| Polymorphism, Single Nucleotide | 1 | 2018 | 4642 | 0.070 |
Why?
|
| Histocompatibility Antigens Class I | 2 | 2017 | 247 | 0.060 |
Why?
|
| Postoperative Care | 2 | 2021 | 727 | 0.060 |
Why?
|
| Neoplasms | 2 | 2023 | 15933 | 0.060 |
Why?
|
| Mice, Inbred C57BL | 3 | 2024 | 7054 | 0.060 |
Why?
|
| Brain Neoplasms | 2 | 2019 | 4966 | 0.060 |
Why?
|
| Drug Therapy, Combination | 2 | 2023 | 2344 | 0.060 |
Why?
|
| Heterografts | 2 | 2019 | 738 | 0.060 |
Why?
|
| Lipocalin-2 | 1 | 2024 | 77 | 0.060 |
Why?
|
| Treatment Failure | 2 | 2019 | 1430 | 0.060 |
Why?
|
| Immunophenotyping | 2 | 2021 | 1725 | 0.060 |
Why?
|
| Chyle | 1 | 2024 | 22 | 0.060 |
Why?
|
| Animals | 8 | 2024 | 61554 | 0.060 |
Why?
|
| Alveolar Epithelial Cells | 1 | 2024 | 51 | 0.060 |
Why?
|
| DNA Copy Number Variations | 2 | 2021 | 1576 | 0.060 |
Why?
|
| Stents | 1 | 2010 | 1002 | 0.060 |
Why?
|
| Signal Transduction | 2 | 2021 | 12044 | 0.060 |
Why?
|
| B-Lymphocytes | 2 | 2020 | 1421 | 0.060 |
Why?
|
| Cell Line, Tumor | 4 | 2021 | 14873 | 0.060 |
Why?
|
| Fecal Microbiota Transplantation | 1 | 2024 | 168 | 0.060 |
Why?
|
| Lymphocyte Activation | 2 | 2020 | 1719 | 0.060 |
Why?
|
| Software | 2 | 2022 | 1358 | 0.060 |
Why?
|
| Mice, SCID | 2 | 2019 | 1825 | 0.050 |
Why?
|
| Mice | 5 | 2024 | 35477 | 0.050 |
Why?
|
| Carcinogens | 1 | 2024 | 389 | 0.050 |
Why?
|
| Drug Administration Schedule | 2 | 2019 | 3533 | 0.050 |
Why?
|
| Infant | 1 | 2018 | 14045 | 0.050 |
Why?
|
| Aneuploidy | 1 | 2024 | 383 | 0.050 |
Why?
|
| Tobacco Products | 1 | 2024 | 157 | 0.050 |
Why?
|
| Mice, Knockout | 2 | 2024 | 5692 | 0.050 |
Why?
|
| Laparoscopy | 1 | 2011 | 1304 | 0.050 |
Why?
|
| Receptors, Adrenergic, beta | 1 | 2002 | 100 | 0.050 |
Why?
|
| Income | 1 | 2023 | 235 | 0.050 |
Why?
|
| Biomarkers | 3 | 2022 | 5054 | 0.050 |
Why?
|
| Ecosystem | 1 | 2022 | 117 | 0.050 |
Why?
|
| Matched-Pair Analysis | 1 | 2021 | 100 | 0.050 |
Why?
|
| Plasma Cells | 1 | 2022 | 197 | 0.050 |
Why?
|
| Prescriptions | 1 | 2021 | 60 | 0.050 |
Why?
|
| Child, Preschool | 1 | 2018 | 17095 | 0.050 |
Why?
|
| Carcinoma, Large Cell | 1 | 2021 | 98 | 0.050 |
Why?
|
| Neoplasm, Residual | 2 | 2018 | 1761 | 0.050 |
Why?
|
| Organoids | 1 | 2024 | 329 | 0.050 |
Why?
|
| Smoking | 2 | 2021 | 2555 | 0.050 |
Why?
|
| Intercostal Nerves | 1 | 2020 | 31 | 0.050 |
Why?
|
| New York | 2 | 2010 | 103 | 0.040 |
Why?
|
| Neck | 1 | 2022 | 395 | 0.040 |
Why?
|
| T-Lymphocytes, Helper-Inducer | 1 | 2021 | 217 | 0.040 |
Why?
|
| Thymectomy | 1 | 2020 | 80 | 0.040 |
Why?
|
| Mutation Rate | 1 | 2021 | 220 | 0.040 |
Why?
|
| Aftercare | 1 | 2021 | 251 | 0.040 |
Why?
|
| Chromosomal Instability | 1 | 2021 | 228 | 0.040 |
Why?
|
| Thyroidectomy | 1 | 2022 | 489 | 0.040 |
Why?
|
| Hospitals | 1 | 2023 | 483 | 0.040 |
Why?
|
| Mitotic Index | 1 | 2020 | 162 | 0.040 |
Why?
|
| Cluster Analysis | 1 | 2022 | 1075 | 0.040 |
Why?
|
| Canada | 1 | 2020 | 443 | 0.040 |
Why?
|
| Metaplasia | 1 | 2021 | 388 | 0.040 |
Why?
|
| Mutagenesis | 1 | 2021 | 511 | 0.040 |
Why?
|
| Tumor Escape | 1 | 2021 | 247 | 0.040 |
Why?
|
| Hyperplasia | 1 | 2021 | 571 | 0.040 |
Why?
|
| Antioxidants | 1 | 2002 | 519 | 0.040 |
Why?
|
| Drainage | 1 | 2021 | 462 | 0.040 |
Why?
|
| Drug Prescriptions | 1 | 2021 | 311 | 0.040 |
Why?
|
| Self Report | 1 | 2023 | 798 | 0.040 |
Why?
|
| Anesthetics, Local | 1 | 2020 | 179 | 0.040 |
Why?
|
| Antigens, CD20 | 1 | 2019 | 207 | 0.040 |
Why?
|
| Adenosine | 1 | 2020 | 292 | 0.040 |
Why?
|
| Cranial Irradiation | 1 | 2020 | 321 | 0.040 |
Why?
|
| Data Interpretation, Statistical | 1 | 2021 | 483 | 0.040 |
Why?
|
| Adaptation, Psychological | 1 | 2023 | 784 | 0.040 |
Why?
|
| Cerebellum | 1 | 2002 | 467 | 0.040 |
Why?
|
| Lymphocyte Count | 1 | 2020 | 485 | 0.040 |
Why?
|
| Clonal Evolution | 1 | 2020 | 250 | 0.040 |
Why?
|
| Quebec | 1 | 2018 | 20 | 0.040 |
Why?
|
| Immunologic Memory | 1 | 2020 | 381 | 0.040 |
Why?
|
| Nerve Block | 1 | 2020 | 185 | 0.040 |
Why?
|
| Double-Blind Method | 1 | 2024 | 2582 | 0.040 |
Why?
|
| Myeloid Cells | 1 | 2019 | 272 | 0.040 |
Why?
|
| Disease Susceptibility | 1 | 2021 | 548 | 0.040 |
Why?
|
| Thoracoscopy | 1 | 2019 | 103 | 0.040 |
Why?
|
| Quality of Life | 2 | 2023 | 4794 | 0.040 |
Why?
|
| Cetuximab | 1 | 2020 | 474 | 0.040 |
Why?
|
| Dietary Supplements | 1 | 2002 | 551 | 0.040 |
Why?
|
| Clinical Decision-Making | 1 | 2022 | 536 | 0.040 |
Why?
|
| Operative Time | 1 | 2019 | 254 | 0.040 |
Why?
|
| North America | 1 | 2018 | 341 | 0.040 |
Why?
|
| Comparative Effectiveness Research | 1 | 2018 | 116 | 0.040 |
Why?
|
| Glycolysis | 1 | 2020 | 528 | 0.040 |
Why?
|
| Healthcare Disparities | 1 | 2023 | 658 | 0.040 |
Why?
|
| Radiation Tolerance | 1 | 2020 | 639 | 0.040 |
Why?
|
| Mice, Inbred NOD | 1 | 2019 | 896 | 0.030 |
Why?
|
| Single-Cell Analysis | 1 | 2021 | 562 | 0.030 |
Why?
|
| Immunity, Innate | 1 | 2021 | 697 | 0.030 |
Why?
|
| Histocompatibility Antigens Class II | 1 | 2017 | 187 | 0.030 |
Why?
|
| T-Lymphocytes, Regulatory | 1 | 2021 | 705 | 0.030 |
Why?
|
| CD57 Antigens | 1 | 2016 | 22 | 0.030 |
Why?
|
| Pain Measurement | 1 | 2020 | 1022 | 0.030 |
Why?
|
| HLA-A2 Antigen | 1 | 2017 | 172 | 0.030 |
Why?
|
| Statistics, Nonparametric | 1 | 2018 | 986 | 0.030 |
Why?
|
| Antigens, Differentiation, Myelomonocytic | 1 | 2016 | 144 | 0.030 |
Why?
|
| Evolution, Molecular | 1 | 2020 | 866 | 0.030 |
Why?
|
| Glucose | 1 | 2021 | 1209 | 0.030 |
Why?
|
| Mastectomy, Segmental | 1 | 2021 | 1050 | 0.030 |
Why?
|
| Feasibility Studies | 1 | 2021 | 2364 | 0.030 |
Why?
|
| Randomized Controlled Trials as Topic | 1 | 2023 | 2663 | 0.030 |
Why?
|
| Recurrence | 1 | 2023 | 4880 | 0.030 |
Why?
|
| Neoplasm Grading | 1 | 2020 | 1824 | 0.030 |
Why?
|
| Oxygenases | 1 | 2014 | 26 | 0.030 |
Why?
|
| Repressor Proteins | 1 | 2022 | 1716 | 0.030 |
Why?
|
| Gene Frequency | 1 | 2017 | 1247 | 0.030 |
Why?
|
| Radiography, Thoracic | 1 | 2017 | 477 | 0.030 |
Why?
|
| Indoles | 1 | 2020 | 1029 | 0.030 |
Why?
|
| Computational Biology | 1 | 2021 | 1295 | 0.030 |
Why?
|
| Recovery of Function | 1 | 2018 | 686 | 0.030 |
Why?
|
| Radiation Dosage | 1 | 2019 | 1042 | 0.030 |
Why?
|
| Aging | 1 | 2002 | 1531 | 0.030 |
Why?
|
| Machine Learning | 1 | 2017 | 365 | 0.030 |
Why?
|
| Medicare | 1 | 2019 | 926 | 0.030 |
Why?
|
| DNA Mutational Analysis | 1 | 2020 | 2357 | 0.030 |
Why?
|
| Chromosome Aberrations | 1 | 2021 | 2035 | 0.030 |
Why?
|
| T-Lymphocyte Subsets | 1 | 2017 | 589 | 0.030 |
Why?
|
| Esophageal pH Monitoring | 1 | 2012 | 7 | 0.030 |
Why?
|
| Practice Patterns, Physicians' | 1 | 2021 | 1303 | 0.030 |
Why?
|
| Ultrasonography | 1 | 2019 | 1929 | 0.030 |
Why?
|
| Lymphocytes | 1 | 2018 | 1273 | 0.030 |
Why?
|
| Manometry | 1 | 2012 | 71 | 0.030 |
Why?
|
| Biopsy | 1 | 2020 | 3488 | 0.030 |
Why?
|
| Comorbidity | 1 | 2019 | 2394 | 0.030 |
Why?
|
| Fundoplication | 1 | 2012 | 70 | 0.030 |
Why?
|
| Societies, Medical | 1 | 2018 | 1319 | 0.020 |
Why?
|
| Genome, Human | 1 | 2020 | 1896 | 0.020 |
Why?
|
| Precision Medicine | 1 | 2020 | 1210 | 0.020 |
Why?
|
| Oximetry | 1 | 2012 | 190 | 0.020 |
Why?
|
| Peptides | 1 | 2017 | 1503 | 0.020 |
Why?
|
| Antigens, CD | 1 | 2016 | 1420 | 0.020 |
Why?
|
| Remission Induction | 1 | 2017 | 3657 | 0.020 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 1 | 2017 | 3587 | 0.020 |
Why?
|
| Amino Acid Sequence | 1 | 2017 | 4542 | 0.020 |
Why?
|
| Xenograft Model Antitumor Assays | 1 | 2019 | 3924 | 0.020 |
Why?
|
| Phenotype | 1 | 2021 | 6503 | 0.020 |
Why?
|
| Dose-Response Relationship, Drug | 1 | 2017 | 5055 | 0.020 |
Why?
|
| Preoperative Period | 1 | 2010 | 347 | 0.020 |
Why?
|
| Diagnosis, Differential | 1 | 2018 | 4838 | 0.020 |
Why?
|
| Models, Biological | 1 | 2018 | 3189 | 0.020 |
Why?
|
| Radiotherapy Dosage | 1 | 2017 | 4020 | 0.020 |
Why?
|
| Algorithms | 1 | 2019 | 3904 | 0.020 |
Why?
|
| Drug Resistance, Neoplasm | 1 | 2020 | 5417 | 0.020 |
Why?
|
| Cell Proliferation | 1 | 2018 | 7232 | 0.020 |
Why?
|
| Referral and Consultation | 1 | 2010 | 933 | 0.010 |
Why?
|
| Magnetic Resonance Imaging | 1 | 2019 | 7899 | 0.010 |
Why?
|
| Cucumis sativus | 1 | 2002 | 1 | 0.010 |
Why?
|
| Spirulina | 1 | 2002 | 3 | 0.010 |
Why?
|
| Case-Control Studies | 1 | 2012 | 6240 | 0.010 |
Why?
|
| Iontophoresis | 1 | 2002 | 16 | 0.010 |
Why?
|
| Malus | 1 | 2002 | 8 | 0.010 |
Why?
|
| Malondialdehyde | 1 | 2002 | 50 | 0.010 |
Why?
|
| Rats, Inbred F344 | 1 | 2002 | 235 | 0.010 |
Why?
|
| Phytotherapy | 1 | 2002 | 101 | 0.010 |
Why?
|
| Electrophysiology | 1 | 2002 | 352 | 0.010 |
Why?
|
| Neural Inhibition | 1 | 2002 | 152 | 0.010 |
Why?
|
| Norepinephrine | 1 | 2002 | 283 | 0.010 |
Why?
|
| Purkinje Cells | 1 | 2002 | 164 | 0.010 |
Why?
|
| gamma-Aminobutyric Acid | 1 | 2002 | 279 | 0.010 |
Why?
|
| Models, Animal | 1 | 2002 | 653 | 0.010 |
Why?
|
| Bacterial Proteins | 1 | 2002 | 1090 | 0.010 |
Why?
|
| Rats | 1 | 2002 | 6404 | 0.010 |
Why?
|